Nasopharyngeal Cancer

Nasopharyngeal cancer originates in the upper throat behind the nose, an area rich in lymphatic tissue.

It’s more prevalent in certain regions and linked to Epstein-Barr virus (EBV).

This cancer often presents late due to vague early symptoms like ear fullness or nasal blockage.

Overview And Clinical Background

It develops in the nasopharynx and often spreads to lymph nodes early.

Viral, genetic, and dietary factors contribute to risk.

Primary cause:Associated with Epstein-Barr virus infection.

Prevalence:Common in Asia and the Middle East.

Nature:Highly radiosensitive, allowing effective non-surgical treatment.

Symptoms resemble chronic sinusitis, delaying diagnosis.

Neck swelling is often the first sign.

Neck mass:Enlarged lymph node due to metastasis.

Ear blockage:Tumor affects Eustachian tube function.

Nosebleeds:Result from mucosal irritation.

Nasopharyngoscopy and biopsy confirm diagnosis, supported by imaging and EBV tests.

Endoscopic exam:Visualizes nasopharyngeal lesion.

MRI/CT:Assesses local and nodal spread.

EBV titer:Helps in diagnosis and monitoring.

Treatment focuses on radiotherapy, often with chemotherapy.

Surgery is rarely needed.

Radiation therapy:Mainstay for localized disease.

Chemoradiation:Used in advanced stages for better control.

Surgical salvage:For residual or recurrent tumors.

Most patients respond well to radiotherapy.

Prognosis improves with early-stage diagnosis.

CureU Healthcare offers precision radiotherapy, ENT oncology teams, and EBV-based diagnostic support for nasopharyngeal cancers.

Nasopharyngeal cancer, though rare, is treatable with early detection and integrated radiation-based management.